Shares of Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. Get Disc Medicine alerts:View Our Latest Stock Report on IRONDisc Medicine Stock PerformanceNASDAQ:IRON opened at $77.44 on Friday. Disc Medicine News SummaryHere are the key news stories impacting Disc Medicine this week:Positive Sentiment: HC Wainwright maintained its Buy rating and raised its price target to $120 . By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options. Further ReadingReceive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.